ENTRY       D09932                      Drug
NAME        Moxetumomab pasudotox (USAN/INN);
            Moxetumomab pasudotox-tdfk;
            Lumoxiti (TN)
PRODUCT     MOXETUMOMAB PASUDOTOX (AstraZeneca Pharmaceuticals LP)
FORMULA     C2804H4339N783O870S14
EXACT_MASS  63348.5445
MOL_WEIGHT  63387.0886
REMARK      ATC code: L01FB02
            Product: D09932<US>
EFFICACY    Antineoplastic, Anti-CD22 antibody
  DISEASE   Hairy-cell leukemia [DS:H00006]
  TYPE      Antibody-drug conjugate
TARGET      CD22 (SIGLEC2) [HSA:933] [KO:K06467]
  PATHWAY   hsa04514(933)  Cell adhesion molecules
            hsa04640(933)  Hematopoietic cell lineage
            hsa04662(933)  B cell receptor signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FB CD22 (Clusters of Differentiation 22) inhibitors
                 L01FB02 Moxetumomab pasudotox
                  D09932  Moxetumomab pasudotox (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Moxetumomab Pasudotox
                D09932  Moxetumomab pasudotox (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Cell adhesion molecules: Ig superfamiy
               SIGLEC family
                CD22 (SIGLEC2)
                 D09932  Moxetumomab pasudotox (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09932
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09932
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09932
DBLINKS     CAS: 1020748-57-5
            PubChem: 135626666
///
